Cologuard Test

Colon cancer is one of the few cancers you can catch before it becomes cancer at all. The lining of your colon develops slow-growing growths called polyps, and certain polyps eventually turn malignant over many years. Catching them early, while they are still polyps or while a cancer is still localized, dramatically improves your odds.

Cologuard is the most sensitive at-home stool test currently available for finding colon cancer. You collect a single stool sample at home, ship it to a lab, and the lab looks for tumor DNA shed by abnormal cells along with traces of hidden blood. It is the closest thing to a colonoscopy that does not require a colonoscopy.

What This Test Actually Measures

Polyps and colon cancers shed cells into stool. Cologuard, formally known as a multitarget stool DNA test (mt-sDNA), looks for two kinds of clues in those shed cells: specific DNA changes typical of colon cancer and a protein called hemoglobin that signals hidden bleeding. Together these clues do a much better job of catching cancer than looking for blood alone.

The DNA component scans for mutations in a gene called KRAS (a gene commonly altered in colon tumors) and chemical changes called methylation on two other genes (BMP3 and NDRG4). The blood component is essentially a built-in fecal immunochemical test (FIT), the same test many doctors use on its own. A computer combines all of these signals into a single positive or negative result.

Catching Cancer and Advanced Polyps

In the original landmark trial of nearly 10,000 average-risk adults, Cologuard caught about 92 out of every 100 colon cancers. The newer next-generation version of the test catches roughly 94 out of every 100. That is the level of cancer detection most people associate with colonoscopy itself.

Cologuard is less sensitive for the precancerous lesions called advanced adenomas, the larger or more dangerous polyps that may turn into cancer over years. The original test catches around 42 out of every 100 of these lesions, and the next-generation test catches about 43 out of every 100. That is roughly twice the detection rate of FIT alone, but well below colonoscopy. The trade-off is that you avoid the prep, the sedation, and the procedure itself.

The Trade-off: False Alarms

The same DNA-and-blood combination that gives Cologuard its high cancer sensitivity also produces more false alarms than a stool blood test alone. In an average-risk screening population, specificity for people without advanced disease is roughly 87 percent for the original test and around 91 percent for the next-generation version. In plain terms, about 9 to 13 out of every 100 people without significant disease will get a positive result that turns out to be benign.

In real-world primary care data, of those who tested positive and went on to colonoscopy, about 4 percent had colon cancer and 24 percent had advanced adenomas. The remaining 73 percent had no cancer or advanced precancerous lesion. A positive result is not a diagnosis. It is a strong signal to look more closely with a colonoscopy.

How Cologuard Compares to FIT and Colonoscopy

FIT is cheaper and slightly more specific, but it misses far more cancers and advanced polyps. Colonoscopy is still the gold standard because it can both find and remove polyps in the same visit. Cologuard sits between them: it detects cancer almost as well as colonoscopy in studies, beats FIT on detection of advanced lesions, and never requires bowel prep or sedation.

Source: Imperiale et al. 2014 (NEJM), Imperiale et al. 2024 (NEJM), Ebner et al. 2025 meta-analysis.

What this means for you: if you are willing to do a colonoscopy, that remains the most thorough way to both detect and remove polyps in a single visit. If you are not, Cologuard is the strongest noninvasive alternative, with cancer detection that approaches colonoscopy and far better polyp detection than FIT.

How to Read Your Result

Unlike most lab tests, Cologuard reports a single positive or negative result rather than a number on a continuum. The lab combines DNA and blood signals into an algorithm that decides whether the overall picture looks more like normal stool or like stool from someone with cancer or an advanced polyp. The thresholds are built into the test and not user-adjustable.

These categories come from average-risk screening populations in the FDA validation trials. Your individual probability of cancer or advanced polyps after a positive result depends on your age, family history, and other risk factors.

What this means for you: a positive Cologuard always requires a follow-up colonoscopy. Skipping that step is the single biggest mistake you can make with this test. The whole value of Cologuard depends on what you do with a positive result.

Why Repeat Testing Matters

A single negative Cologuard is not a permanent all-clear. Polyps can grow between screenings, and the test misses some advanced adenomas. Modeling and the original validation studies support repeating Cologuard every 3 years if your result is negative, which is shorter than the every-5-years cadence sometimes used for guideline minimums.

Real-world studies confirm the value of staying on schedule. On the second round of testing, the test still detected colon neoplasia at a high rate, with similar performance to the first round. If you are actively managing your colon cancer risk, a 3-year cadence after a negative result is the standard, and you should know your number by age 45 at the latest, ideally earlier if you have a family history.

When Results Can Be Misleading

Cologuard is a single snapshot. Several factors can produce results that do not reflect your true colon health, and a few situations make the test unreliable enough that you should consider a different approach.

• Bleeding hemorrhoids or menstrual blood: the blood component of Cologuard cannot tell where blood in stool came from, so visible bleeding from anywhere along the GI tract or contamination from a menstrual period can trigger a positive result.
• Ulcers, diverticulitis, or other non-cancer GI bleeding: in studies of positive tests, about 21 to 24 percent of people had non-neoplastic bleeding sources that explained the result rather than cancer or polyps.
• Active inflammatory bowel disease (Crohn's, ulcerative colitis): Cologuard was not designed or validated for surveillance in IBD. People with active IBD should follow specialist-driven colonoscopy schedules instead.
• Recent colonoscopy with polyp removal: any residual bleeding from polyp sites can produce a positive result that does not reflect new disease.

Decision Pathway for an Abnormal Result

A positive Cologuard means one thing: schedule a colonoscopy. Not another stool test, not a CT scan, not a wait-and-see. The colonoscopy serves both as the diagnostic step and as the treatment, since most precancerous polyps can be removed during the same procedure. Most positives that turn out to be cancer are caught at stage I or II, when surgical cure rates are highest.

If your colonoscopy is normal after a positive Cologuard, that is reassuring but not the end of the conversation. A small number of people in this situation have lesions in the upper GI tract or very small right-sided lesions that are easily missed. Discuss with a gastroenterologist whether additional evaluation is appropriate based on your symptoms, age, and family history. Do not simply assume the Cologuard was wrong and forget about it.

If your result is negative but you have rectal bleeding, unexplained anemia, change in bowel habits, or unintentional weight loss, the negative result does not rule out a problem. Cologuard is a screening test for asymptomatic people. New or persistent symptoms warrant a colonoscopy regardless of what your stool test shows.